FRED-EPI study: Safety and efficacy of FRED/FRED Jr aneurysm treatment in current clinical practice.

IF 3 3区医学 Q2 CLINICAL NEUROLOGY Journal of Neuroradiology Pub Date : 2025-01-09 DOI:10.1016/j.neurad.2024.101240

Laurent Pierot, Denis Herbreteau, Xavier Barreau, Hervé Brunel, Jacques Sedat, Laurent Spelle, Roberto Riva, Olivier Heck, Matthias Gawlitza, Gaultier Marnat, Kevin Janot, Kamel Boubagra, Omer Eker

{"title":"FRED-EPI study: Safety and efficacy of FRED/FRED Jr aneurysm treatment in current clinical practice.","authors":"Laurent Pierot, Denis Herbreteau, Xavier Barreau, Hervé Brunel, Jacques Sedat, Laurent Spelle, Roberto Riva, Olivier Heck, Matthias Gawlitza, Gaultier Marnat, Kevin Janot, Kamel Boubagra, Omer Eker","doi":"10.1016/j.neurad.2024.101240","DOIUrl":null,"url":null,"abstract":"Objective: Flow diversion is increasingly used as an endovascular treatment for intracranial aneurysms. FRED-EPI is a prospective, multicenter, French study, conducted to analyze the safety and efficacy of aneurysm treatment with FRED/FRED Jr (Microvention, AlisoViejo, CA, USA) in current clinical practice.Patients and methods: Patients with intracranial aneurysms treated with FRED and FRED Jr who agreed to participate were prospectively and consecutively included in all French centers using these devices.Results: From June 2020 to January 2022, 135 patients (110 females, 81.5%, and 25 males, 18.5%) with 154 aneurysms were included in 13 French interventional neuroradiology centers. The mean age was 53.9 ± 12.2 years (range: 20 - 77 years). Aneurysm was unruptured in 123 cases (79.9%), ruptured in 4 cases (2.6%), and recanalized in 27 cases (17.5%). Most aneurysms were small (135/154, 87.7%). Aneurysm locations were supraclinoid ICA in 83 (53.9%), cavernous and petrous ICA in 25 (16.2%), anterior cerebral artery or anterior communicating artery in 19 (12.3%), MCA in 7 (4.5%), and posterior circulation in 20 (13.0%). Three patients (2.2%) had hemorrhagic complications (1 delayed aneurysm rupture and 2 delayed remote hematoma) and 3 (2.2%) ischemic complications (2 intrastent thrombosis and 1 stroke related to atherosclerosis) leading to 1-year morbimortality of 4.4%. Complete aneurysm occlusion was reported in 105/139 aneurysms (75.5%).Conclusions: FRED-EPI confirms good safety of aneurysm treatment with FRED/FRED Jr in current clinical practice with 4.4% 1-year morbimortality.","PeriodicalId":50115,"journal":{"name":"Journal of Neuroradiology","volume":"52 1","pages":"101240"},"PeriodicalIF":3.0000,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuroradiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.neurad.2024.101240","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Flow diversion is increasingly used as an endovascular treatment for intracranial aneurysms. FRED-EPI is a prospective, multicenter, French study, conducted to analyze the safety and efficacy of aneurysm treatment with FRED/FRED Jr (Microvention, AlisoViejo, CA, USA) in current clinical practice.

Patients and methods: Patients with intracranial aneurysms treated with FRED and FRED Jr who agreed to participate were prospectively and consecutively included in all French centers using these devices.

Results: From June 2020 to January 2022, 135 patients (110 females, 81.5%, and 25 males, 18.5%) with 154 aneurysms were included in 13 French interventional neuroradiology centers. The mean age was 53.9 ± 12.2 years (range: 20 - 77 years). Aneurysm was unruptured in 123 cases (79.9%), ruptured in 4 cases (2.6%), and recanalized in 27 cases (17.5%). Most aneurysms were small (135/154, 87.7%). Aneurysm locations were supraclinoid ICA in 83 (53.9%), cavernous and petrous ICA in 25 (16.2%), anterior cerebral artery or anterior communicating artery in 19 (12.3%), MCA in 7 (4.5%), and posterior circulation in 20 (13.0%). Three patients (2.2%) had hemorrhagic complications (1 delayed aneurysm rupture and 2 delayed remote hematoma) and 3 (2.2%) ischemic complications (2 intrastent thrombosis and 1 stroke related to atherosclerosis) leading to 1-year morbimortality of 4.4%. Complete aneurysm occlusion was reported in 105/139 aneurysms (75.5%).

Conclusions: FRED-EPI confirms good safety of aneurysm treatment with FRED/FRED Jr in current clinical practice with 4.4% 1-year morbimortality.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

FRED- epi研究：FRED/FRED Jr治疗动脉瘤在当前临床实践中的安全性和有效性

目的：血流分流术越来越多地被用于颅内动脉瘤的血管内治疗。FRED- epi是一项法国的前瞻性、多中心研究，旨在分析FRED/FRED Jr （Microvention, AlisoViejo， CA， USA）在当前临床实践中治疗动脉瘤的安全性和有效性。患者和方法：接受FRED和FRED Jr治疗的颅内动脉瘤患者同意参与前瞻性和连续纳入使用这些装置的所有法国中心。结果：2020年6月至2022年1月，法国13个介入神经放射中心共纳入135例动脉瘤，其中女性110例，占81.5%，男性25例，占18.5%。平均年龄53.9±12.2岁（范围：20 ~ 77岁）。动脉瘤未破裂123例（79.9%），破裂4例（2.6%），再通27例（17.5%）。动脉瘤以小为主（135/154,87.7%）。动脉瘤的位置为：颈内突上动脉瘤83例（53.9%），海绵状及岩状动脉瘤25例（16.2%），大脑前动脉或前交通动脉19例（12.3%），MCA 7例（4.5%），后循环20例（13.0%）。3例（2.2%）患者出现出血性并发症（1例迟发性动脉瘤破裂，2例迟发性远处血肿）和3例（2.2%）缺血性并发症（2例血管内血栓形成，1例动脉粥样硬化相关中风），导致1年死亡率为4.4%。139例动脉瘤中有105例（75.5%）完全性闭塞。结论：FRED- epi在目前的临床实践中证实了FRED/FRED Jr治疗动脉瘤的良好安全性，1年死亡率为4.4%。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Neuroradiology 医学-核医学

CiteScore

6.10

自引率

5.70%

发文量

142

审稿时长

6-12 weeks

期刊介绍： The Journal of Neuroradiology is a peer-reviewed journal, publishing worldwide clinical and basic research in the field of diagnostic and Interventional neuroradiology, translational and molecular neuroimaging, and artificial intelligence in neuroradiology. The Journal of Neuroradiology considers for publication articles, reviews, technical notes and letters to the editors (correspondence section), provided that the methodology and scientific content are of high quality, and that the results will have substantial clinical impact and/or physiological importance.